Blastocystis hominis: Difference between revisions
From IDWiki
Blastocystis hominis
No edit summary |
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations") |
||
| Line 7: | Line 7: | ||
* Prevalence higher in developing than developed countries |
* Prevalence higher in developing than developed countries |
||
== Clinical |
== Clinical Manifestations == |
||
* Unclear if it causes a clinical syndrome; may be strain-dependent |
* Unclear if it causes a clinical syndrome; may be strain-dependent |
||
* Has been implicated in acute diarrhea, chronic diarrhea, bloating, flatulence, abdominal cramping, and fatigue, as well as irritable bowel syndrome |
* Has been implicated in acute diarrhea, chronic diarrhea, bloating, flatulence, abdominal cramping, and fatigue, as well as irritable bowel syndrome |
||
Revision as of 04:28, 23 July 2020
Background
Epidemiology
- Worldwide, but varies by subtype
- Subtype 3 most common worldwide in human
- Subtype 4 is in Europe
- Prevalence higher in developing than developed countries
Clinical Manifestations
- Unclear if it causes a clinical syndrome; may be strain-dependent
- Has been implicated in acute diarrhea, chronic diarrhea, bloating, flatulence, abdominal cramping, and fatigue, as well as irritable bowel syndrome
Diagnosis
- Stool microscopy with trichrome stain
- In vitro cell culture
- PCR is standard
Management
- Eliminate all other causes of symptoms
- If still symptomatic, can consider treatment
- Nitazoxanide 500 mg po bid for 3 days
- Can also try: metronidazole 750 mg po tid for 10 days, trimethoprim-sulfamethoxazole DS 1 tab po bid for 7 days, and iodoquinol 650 mg po tid for 20 days
- Unclear which, if any, is helpful
